• Disease
  • Advanced
  • Advanced Melanoma
  • Caroline Robert

    Prominent publications by Caroline Robert

    KOL Index score: 25114

    BACKGROUND: Results from phase 2 and 3 trials in patients with advanced melanoma have shown significant improvements in the proportion of patients achieving an objective response and prolonged progression-free survival with the combination of nivolumab (an anti-PD-1 antibody) plus ipilimumab (an anti-CTLA-4 antibody) compared with ipilimumab alone. We report 2-year overall survival data from a randomised controlled trial assessing this treatment in previously untreated advanced ...

    Also Ranks for: Ipilimumab Patients |  advanced melanoma |  survival outcomes |  combined nivolumab |  phase 2
    KOL Index score: 23876

    BACKGROUND: Combined BRAF-MEK inhibitor therapy is the standard of care for BRAFV600-mutant advanced melanoma. We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma.

    METHODS: COLUMBUS was conducted as a two-part, randomised, open-label phase 3 study at 162 hospitals in 28 countries. Eligible patients were aged 18 years or older ...

    Also Ranks for: Encorafenib Binimetinib |  vemurafenib patients |  mutant melanoma |  3 trial |  braf inhibitor
    KOL Index score: 23229

    BACKGROUND: Encorafenib plus binimetinib and encorafenib alone improved progression-free survival compared with vemurafenib in patients with BRAFV600-mutant melanoma in the COLUMBUS trial. Here, we report the results of the secondary endpoint of overall survival.

    METHODS: COLUMBUS was a two-part, randomised, open-label, phase 3 study done at 162 hospitals in 28 countries. Eligible patients were aged at least 18 years with histologically confirmed, locally advanced, unresectable, or ...

    Also Ranks for: Encorafenib Binimetinib |  3 trial |  vemurafenib patients |  mutant melanoma |  middle aged mutation
    KOL Index score: 23158

    BACKGROUND: Patients with melanoma that progresses on ipilimumab and, if BRAF(V600) mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options. We assessed the efficacy and safety of two pembrolizumab doses versus investigator-choice chemotherapy in patients with ipilimumab-refractory melanoma.

    METHODS: We carried out a randomised phase 2 trial of patients aged 18 years or older from 73 hospitals, clinics, and academic medical centres in 12 countries who had confirmed ...

    Also Ranks for: Patients Pembrolizumab |  2 trial |  choice chemotherapy |  treatment ipilimumab |  progressionfree survival
    KOL Index score: 21834

    BACKGROUND: Ipilimumab is an approved treatment for patients with advanced melanoma. We aimed to assess ipilimumab as adjuvant therapy for patients with completely resected stage III melanoma at high risk of recurrence.

    METHODS: We did a double-blind, phase 3 trial in patients with stage III cutaneous melanoma (excluding lymph node metastasis ≤1 mm or in-transit metastasis) with adequate resection of lymph nodes (ie, the primary cutaneous melanoma must have been completely excised with ...

    Also Ranks for: Adjuvant Ipilimumab |  3 trial |  complete resection |  iii melanoma |  risk stage
    KOL Index score: 20881

    BACKGROUND: Interim analyses of the phase 3 KEYNOTE-006 study showed superior overall and progression-free survival of pembrolizumab versus ipilimumab in patients with advanced melanoma. We present the final protocol-specified survival analysis.

    METHODS: In this multicentre, open-label, randomised, phase 3 trial, we recruited patients from 87 academic institutions, hospitals, and cancer centres in 16 countries (Australia, Austria, Belgium, Canada, Chile, Colombia, France, Germany, ...

    Also Ranks for: Advanced Melanoma |  3 study |  pembrolizumab ipilimumab |  humanized antineoplastic agents |  antibodies monoclonal
    KOL Index score: 20337

    BACKGROUND: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 trial comparing the benefit-risk profile of ipilimumab 10 mg/kg versus 3 mg/kg.

    METHODS: This randomised, double-blind, multicentre, phase 3 trial was done in 87 centres in 21 countries worldwide. Patients with untreated or previously treated ...

    Also Ranks for: Ipilimumab 3 |  metastatic melanoma |  patients 10 |  treatment adverse |  braf inhibitors
    KOL Index score: 19356

    BACKGROUND: The EORTC 18071 phase 3 trial compared adjuvant ipilimumab with placebo in patients with stage III melanoma. The primary endpoint, recurrence-free survival, was significantly longer in the ipilimumab group than in the placebo group. Investigator-reported toxic effects of ipilimumab consisted mainly of skin, gastrointestinal, endocrine, and hepatic immune-related adverse events. Adjuvant treatment with ipilimumab in this setting was approved in October, 2014, by the US Food ...

    Also Ranks for: Adjuvant Ipilimumab |  3 trial |  complete resection |  stage iii melanoma |  average score
    KOL Index score: 19164

    Adjuvant interferon has modest activity in melanoma patients at high risk for relapse. Patient selection is important; stage and ulceration of the primary tumour are key prognostic factors.

    METHODS: In this post hoc meta-analysis of European Organisation for Research and Treatment of Cancer (EORTC) trials 18952 (intermediate doses of interferon α-2b [IFN] versus observation in stage IIb-III patients) and 18991 (pegylated [PEG]-IFN versus observation in stage III patients), the predictive ...

    Also Ranks for: Phase Iii |  rfs dmfs |  eortc 18952 |  ifn pegifn |  interferon efficacy
    KOL Index score: 18751

    BACKGROUND: Pembrolizumab improved progression-free survival and overall survival versus ipilimumab in patients with advanced melanoma and is now a standard of care in the first-line setting. However, the optimal duration of anti-PD-1 administration is unknown. We present results from 5 years of follow-up of patients in KEYNOTE-006.

    METHODS: KEYNOTE-006 was an open-label, multicentre, randomised, controlled, phase 3 study done at 87 academic institutions, hospitals, and cancer centres in ...

    Also Ranks for: Advanced Melanoma |  pembrolizumab patients |  5 years |  ipilimumab 3 |  efficacy safety
    KOL Index score: 18587

    BACKGROUND: Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has shown antitumour activity in patients with BRAF-mutant melanoma and in preclinical models when combined with chemotherapy. This study was designed to look for a signal of improved efficacy by comparing the combination of selumetinib and dacarbazine with dacarbazine alone.

    METHODS: This double-blind, randomised, placebo-controlled phase 2 ...

    Also Ranks for: Selumetinib Dacarbazine |  metastatic melanoma |  mutational analysis |  progressionfree survival |  braf mutation
    KOL Index score: 18519

    BACKGROUND: Dabrafenib plus trametinib improves clinical outcomes in BRAFV600-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus trametinib has not been studied in active melanoma brain metastases. Here, we report results from the phase 2 COMBI-MB trial. Our aim was to build on the current body of evidence of targeted therapy in melanoma brain metastases through an evaluation of dabrafenib plus trametinib in patients with BRAFV600-mutant ...

    Also Ranks for: Melanoma Brain |  dabrafenib trametinib |  intracranial response |  2 trial |  patients cohort
    KOL Index score: 18340

    BACKGROUND: In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly longer overall and progression-free survival than those treated with vemurafenib alone. Here, we present the effects of treatments on health-related quality of life (HRQoL), an exploratory endpoint in the COMBI-v study.

    METHODS: COMBI-v was an open-label, randomised ...

    Also Ranks for: Combination Therapy |  dabrafenib trametinib |  progression disease |  primary endpoint |  phase 3
    KOL Index score: 18126

    Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic melanoma. This study was continued to assess 3-year landmark efficacy and safety after ≥36-month follow-up for all living patients.

    Patients and methods: This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant ...

    Also Ranks for: Dabrafenib Trametinib |  mutant melanoma |  3 study |  braf v600e |  monotherapy patients


    Caroline Robert: Influence Statistics

    Sample of concepts for which Caroline Robert is among the top experts in the world.
    Concept World rank
    downstream lymph nodes #1
    unresectable gist imatinib #1
    sunitinib efficacy treatment #1
    lselectinrnatransfected #1
    l1 proximity #1
    clinical response colitis #1
    amep metargidin peptide #1
    meki mek inhibitors #1
    tremelimumab melanoma #1
    grade pyrexia #1
    iraes ici discontinuation #1
    controlled trials melanoma #1
    melanoma population patients #1
    ipilimumab pembrolizumab #1
    paradigm tumor #1
    ipilimumab rate #1
    lymph nodes pln #1
    braf v600 #1
    week pembrolizumab q2w #1
    melanoma combination therapies #1
    immunological synapse gjs #1
    snb primary excision #1
    q2w pembrolizumab q3w #1
    conventional chemotherapies #1
    patients mmtnm #1
    immunological chemotherapy #1
    pharmacodynamic activity dose #1
    hepatic iraes severity #1
    gjs cytotoxic lymphocyte #1
    stratification factor ulceration #1
    study 76 patients #1
    50 2 weeks #1
    electrotransfer patients #1
    promising agents development #1
    effets secondaires #1
    mmtnm scctnm #1
    melanomaspecific #1
    cpdags #1
    patients publication antibodies #1
    urelumab agonist antibody #1
    dendritic cells icos #1
    paclitaxel pfs #1
    dermatologic symptoms sorafenib #1
    new toxicities #1
    cutaneous reactions sorafenib #1
    irae rfs #1
    interim analysis patients #1
    abscopal antitumor #1
    dermatologic symptoms #1
    evidence tumour burden #1

    Key People For Advanced Melanoma

    Top KOLs in the world
    Dirk Schadendorf
    melanoma patients advisory consultancy braf v600
    Caroline Robert
    advanced melanoma braf v600 advisory consultancy
    Frank Stephen Hodi
    advanced melanoma brain metastases nivolumab ipilimumab
    Reinhard G Dummer
    metastatic melanoma cutaneous lymphomas advisory consultancy
    Jean Jacques Grob
    advisory consultancy advanced melanoma grant funding
    Jeffrey S Weber
    metastatic melanoma advisory consultancy complete resection

    Caroline Robert:Expert Impact

    Concepts for whichCaroline Roberthas direct influence:Advanced melanoma,  Metastatic melanoma,  Braf v600,  Advisory consultancy,  Complete resection.

    Caroline Robert:KOL impact

    Concepts related to the work of other authors for whichfor which Caroline Robert has influence:Metastatic melanoma,  Immune checkpoint inhibitors,  Cancer immunotherapy,  Tumor microenvironment,  Brain metastases,  Hepatocellular carcinoma,  Dendritic cells.



    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

    Gustave Roussy, Villejuif, and Paris-Saclay University, Orsay, France. | Paris-Saclay University, Villejuif, France | Paris-Saclay University, Orsay, France | Gustave Roussy, Villejuif, and Paris-Saclay University, Orsay, France | Faculté de Médecine